Evolution of toxicity after conformal radiotherapy for prostate cancer

被引:9
作者
Abdalla, I
Ignacio, L
Vaida, F
Mei-Hsu
Awan, A
Jani, A
Mamo, C
Weichselbaum, RR
Vijayakumar, S
机构
[1] Univ Illinois, Chicago Hosp, Dept Radiat Oncol, Chicago, IL 60612 USA
[2] Univ Chicago Hosp, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[3] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[4] Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA
关键词
radiotherapy; prostate cancer; toxicity;
D O I
10.1038/sj.pcan.4500608
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The limiting factor for radiation (RT) dose-escalation is normal tissue toxicity. In dose-escalation studies, it is important to determine the factors associated with toxicity and the length of follow-up period after which a particular RT dose is considered safe. We analyzed 449 prostate cancer patients treated with RT at our institution and followed for a median of 27 months. Genitourinary (GU) and gaustrointerological (GI) complications were graded and analyzed using three different statistical models. Univariate and multivariate analyses were conducted for factors associated with toxicity. There was no RTOG grade 4 or 5 toxicity. Only 23 patients (5%) experienced grade 3 toxicity. After treatment, there was an initial rapid decline in the risk of toxicity following treatment, followed by an increase or stabilization of the toxicity with time of follow-up. The breakpoints between the two periods were 2 y (any toxicity) and 1 y (high toxicity) for GU and 9 months (any toxicity, high toxicity) for GI. Age, dose, fraction size, duration of treatment and hospital of treatment emerge as important factors in the probability of developing toxicity. Our study shows that delivering conventional doses using conformal techniques is associated with minimal high-grade toxicity. However, even within a narrow dose range and fraction size used, differences do emerge which should lead one to be cautious in extending the results of dose escalation study to the community practice without a sufficient follow-up.
引用
收藏
页码:296 / 303
页数:8
相关论文
共 15 条
[1]   Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[2]  
FOLWER FJ, 1996, J CLIN ONCOL, V14, P2258
[3]   Conformal external beam treatment of prostate cancer [J].
Hanks, GE ;
Hanlon, AL ;
Schultheiss, TE ;
Freedman, GM ;
Hunt, M ;
Pinover, WH ;
Movsas, B .
UROLOGY, 1997, 50 (01) :87-92
[4]   Conformal technique dose escalation for prostate cancer: Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen >=10 ng/ml [J].
Hanks, GE ;
Lee, WR ;
Hanlon, AL ;
Hunt, M ;
Kaplan, E ;
Epstein, BE ;
Movsas, B ;
Schultheiss, TE .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (05) :861-868
[5]   Optimization of conformal radiation treatment of prostate cancer: Report of a dose escalation study [J].
Hanks, GE ;
Schultheiss, TE ;
Hanlon, AL ;
Hunt, M ;
Lee, WR ;
Epstein, BE ;
Coia, LR .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (03) :543-550
[6]  
KLIENBAUM DG, 1996, SURVIVAL ANAL, P4
[7]   3-DIMENSIONAL CONFORMAL RADIATION-THERAPY IN LOCALIZED CARCINOMA OF THE PROSTATE - INTERIM-REPORT OF A PHASE-1 DOSE-ESCALATION STUDY [J].
LEIBEL, SA ;
ZELEFSKY, MJ ;
KUTCHER, GJ ;
BURMAN, CM ;
KELSON, S ;
FUKS, Z .
JOURNAL OF UROLOGY, 1994, 152 (05) :1792-1798
[8]   QUALITY-OF-LIFE - RADICAL PROSTATECTOMY VERSUS RADIATION-THERAPY FOR PROSTATE-CANCER [J].
LIM, AJ ;
BRANDON, AH ;
FIEDLER, J ;
BRICKMAN, AL ;
BOYER, CI ;
RAUB, WA ;
SOLOWAY, MS .
JOURNAL OF UROLOGY, 1995, 154 (04) :1420-1425
[9]   BEAMS EYE VIEW BASED PROSTATE TREATMENT PLANNING - IS IT USEFUL [J].
LOW, NN ;
VIJAYAKUMAR, S ;
ROSENBERG, I ;
RUBIN, S ;
VIRUDACHALAM, R ;
SPELBRING, DR ;
CHEN, GTY .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (03) :759-768
[10]   Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31 [J].
Pilepich, MV ;
Caplan, R ;
Byhardt, RW ;
Lawton, CA ;
Gallagher, MJ ;
Mesic, JB ;
Hanks, GE ;
Coughlin, CT ;
Porter, A ;
Shipley, WU ;
Grignon, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :1013-1021